Removing pharmacies’ ability to re-sell drug products to wholesalers would help to prevent medications from being leaked into the gray market, as highlighted in a recent Drug Topicsarticle. NABP Executive Director/Secretary Carmen A. Catizone, MS, RPh, DPh, explained that some pharmacies choosing to resell drugs to wholesalers may not necessarily be violating the law, rather […]

Read More ›

A domain name dispute complaint involving unauthorized use of two NABP trademarks – NABP® and VIPPS® – has been decided in favor of the Association by the National Arbitration Forum. On June 13, 2012, NABP filed a complaint with the National Arbitration Forum against Tarien Kunkleman c/o YourNameMonkey.com (Respondent), regarding registration of the domain name […]

Read More ›

The Los Angeles City Council voted unanimously to adopt an ordinance that would ban medical marijuana retail shops from doing business in the city. The Associated Press (AP) reports that the measure could affect about 900 dispensaries in the area; however, a similar prior ordinance failed to be implemented due to lawsuits and conflicting rulings. […]

Read More ›

NABP recently amended the Model State Pharmacy Act and Model Rules of the National Association of Boards of Pharmacy (Model Act) in its effort to assist the boards of pharmacy as they work to protect the public health. The Model Act was amended by increasing security provisions for pharmacies, adding Model Rules for medical gases, […]

Read More ›

The National Association of Boards of Pharmacy® (NABP®) today issued a report about the continually increasing online counterfeit drug supply and the urgent need for international collaboration among regulators and other public agencies as well as private sector entities. As described in the Internet Drug Outlet Identification Program Progress Report for State and Federal Regulators: […]

Read More ›

As part of the federal initiative to address the prescription drug abuse, misuse, and overdose epidemic, Food and Drug Administration (FDA) has approved a risk evaluation and mitigation strategy (REMS) for extended-release (ER) and long-acting (LA) opioids. The REMS introduces new safety measures designed to reduce risks and improve the safe use of ER and […]

Read More ›

A new Michigan law bans synthetic cannabinoid products, including K2 and Spice, as well as synthetic bath salt products, and the chemicals used to make these products. These synthetic drugs will be classified as Schedule I controlled substances in Michigan “and producers and distributors will be subject to the same penalties as those of other […]

Read More ›

The United States Senate voted against the proposed amendment to the Food and Drug Administration (FDA) Safety and Innovation Act that would have allowed drug importation from Canadian pharmacies on May 24, 2012. The amendment failed in a vote of 43 to 54, as reported by the Partnership for Safe Medicines (PSM). Subsequently, the FDA […]

Read More ›

Since Drug Enforcement Administration (DEA) issued the interim final rule for electronic prescribing of controlled substances (EPCS), a “modest number” of EPCSs have been transmitted across the Surescripts network, reports the company, which is the operator of the largest e-prescription network in the US. In response to questions from industry, Surescripts has provided an Update […]

Read More ›

The National Association of Boards of Pharmacy® (NABP®) has signed the Partnership for Safe Medicines’ (PSM) letter to United States senators to show its support of PSM’s stance that the Prescription Drug User Fee Act should not be amended to allow drug importation by individual consumers. By allowing importation, the secure US drug supply chain […]

Read More ›